In addition, an empirically annotated TYK2 pathway will also allow better targeting of other dermatological and autoimmune conditions, such as psoriatic arthritis and inflammatory dermatitis, as shown in this study, both of which may be best treated with such a therapy. This evidence concerns the gene TYK2 and psoriatic arthritis.